Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 379,500 shares, an increase of 600.2% from the March 31st total of 54,200 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 4.4% of the company’s stock are short sold.
Xilio Therapeutics Stock Up 7.9 %
Shares of XLO stock opened at $1.09 on Friday. The company has a 50 day moving average price of $0.92 and a 200-day moving average price of $1.03. Xilio Therapeutics has a 52 week low of $0.49 and a 52 week high of $3.40. The firm has a market capitalization of $37.57 million, a PE ratio of -0.39 and a beta of -0.12.
Xilio Therapeutics (NASDAQ:XLO – Get Free Report) last announced its earnings results on Monday, April 1st. The company reported ($0.64) earnings per share (EPS) for the quarter. Analysts anticipate that Xilio Therapeutics will post -1.53 earnings per share for the current year.
Insider Buying and Selling at Xilio Therapeutics
Hedge Funds Weigh In On Xilio Therapeutics
An institutional investor recently bought a new position in Xilio Therapeutics stock. PFG Investments LLC purchased a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned approximately 0.09% of Xilio Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 54.29% of the company’s stock.
Xilio Therapeutics Company Profile
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.
Further Reading
- Five stocks we like better than Xilio Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- P/E Ratio Calculation: How to Assess Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.